CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
HFA-152a +2 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06506266
NCT06506266Phase 1Completed

A Randomized, Double-blind, Single-site, Two-way Crossover Phase 1 Study to Assess the Effect of Repeated Doses of Test Propellant (HFA-152a) on Mucociliary Clearance as Compared to Reference Propellant (HFA-134a) in Healthy Male and Female Participants

GlaxoSmithKline·interventional·Posted Jul 17, 2024·Updated Apr 14, 2026

In Brief

A Phase 1 clinical trial evaluating HFA-152a, HFA-134a, and 1 other intervention for Asthma. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The main goal of the study is to assess the effect of the administration of reference propellant \[HFA-134a (1,1,1,2 - Tetrafluoroethane)\] and test propellant \[HFA-152a (1 - Difluoroethane)\] in healthy adults on mucociliary clearance (MCC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
20252026
First PostedJul 17, 2024
Enrollment StartJul 29, 2024
Primary CompletionOct 24, 2024
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 2.0 years ago

Interventions

HFA-152aother

HFA-152a is administered via oral inhalation

HFA-134aother

HFA-134a is administered via oral inhalation

Radiolabeled saline solutionother

Radiolabeled saline solution is administered via oral inhalation